🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Jason A. Wampfler

Mayo Clinic

ORCID: 0009-0007-6918-8135

Also affiliated with WinnMed

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 4%percentile
0.752Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Efficient and Accurate Extracting of Unstructured EHRs on Cancer Therapy Responses for the Development of RECIST Natural Language Processing Tools: Part I, the Corpus

JCO Clinical Cancer Informatics(2020)10.1200/cci.19.00147
Top 27%
0.752DataRank
Top 27%11 citations

Yung‐Hung Luo, Jason A. Wampfler, Samuel M. Rubinstein, Firat Tiryaki, Ashok Kumar +4 more

Papers

Driven by 11 papers — median percentile 73. Top paper: “Efficient and Accurate Extracting of Unstructured EHRs on Cancer Therapy Responses for the Development of RECIST Natural Language Processing Tools: Part I, the Corpus”.

Efficient and Accurate Extracting of Unstructured EHRs on Cancer Therapy Responses for the Development of RECIST Natural Language Processing Tools: Part I, the Corpus

JCO Clinical Cancer Informatics(2020)10.1200/cci.19.00147
Top 27%
0.752DataRank
Top 27%11 citations

Yung‐Hung Luo, Jason A. Wampfler, Samuel M. Rubinstein, Firat Tiryaki, Ashok Kumar +4 more

Risk model‐based management for second primary lung cancer among lung cancer survivors through a validated risk prediction model

Cancer(2023)10.1002/cncr.35069
N/A
0.345DataRank · unranked
9 citations

Sophia J. Luo, Victoria Y. Ding, Julie Wu, Ashok V. Kumar, Jason A. Wampfler +15 more

Prognostic factors in resected pulmonary carcinoid tumors: A retrospective study with 10 years of follow‑up

Oncology Letters(2023)10.3892/ol.2023.13666
N/A
0.165DataRank · unranked
2 citations

Vinicius Ernani, Alex C.H. Liu, Steven E. Schild, Dawn E. Jaroszewski, Steven D. Cassivi +9 more

Targeted therapy‑associated cardiotoxicity in patients with stage‑IV lung cancer with or without cardiac comorbidities

Oncology Reports(2024)10.3892/or.2024.8858
N/A
0DataRank · unranked
10 citations

Dong Li, Jason A. Wampfler, Yung‐Hung Luo, Ashok Kumar, Zhong Gu +7 more

Dermatologic toxicity associated with targeted and immunotherapies in stage-IV non-small cell lung cancer patients: A 14-year cohort

Journal of the American Academy of Dermatology(2024)10.1016/j.jaad.2024.03.029
N/A
0DataRank · unranked
4 citations

Ashok V. Kumar, Zhong Gu, Nikhila Kosuru, Jason A. Wampfler, Pedro Reck dos Santos +6 more

Spatially defined intratumoral immune biomarkers predict recurrent versus second primary tumors in non-small cell lung cancer

Precision Clinical Medicine(2025)10.1093/pcmedi/pbaf001
N/A
0DataRank · unranked
1 citations

Alanna Maguire, Eunhee S. Yi, Yanmei Peng, Jennifer M. Kachergus, András Khoór +14 more

The profile and clinical predicting effect of non-rash dermatologic toxicity related to targeted therapy in stage-IV non-small cell lung cancer patients

BioScience Trends(2025)10.5582/bst.2024.01424
N/A
0DataRank · unranked
0 citations

Collin M. Costello, Zhaoheng Liu, Ashok V. Kumar, Zhong Gu, Nikhila Kosuru +6 more

Lung cancer combined with interstitial lung disease: Controversial role of preexisting hypertension and emphysema observed in a fully followed 20-year patient cohort.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.10556
N/A
0DataRank · unranked
0 citations

Zhaoheng Liu, Jason A. Wampfler, Nansu Zong, Karen L. Swanson, Ping Yang +1 more

Surgical management of both stage III and stage IV pulmonary carcinoid tumors confers survival benefit

JTCVS Open(2025)10.1016/j.xjon.2025.06.005
N/A
0DataRank · unranked
0 citations

Pedro Reck dos Santos, Zhong Gu, Matthew Buras, Juan Farina, Nathan Y. Yu +8 more

Osimertinib in previously EGFR-TKI treated non-small cell lung cancer (NSCLC) patients without T790M mutation: Real-world evidence.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e21631
N/A
0DataRank · unranked
0 citations

Han Liu, Jason A. Wampfler, Henry D. Tazelaar, Yalun Li, Tobias Peikert +7 more

Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation

Journal of Cancer Research and Clinical Oncology(2021)10.1007/s00432-021-03766-5
N/A
0DataRank · unranked
7 citations

Han Liu, Jason A. Wampfler, Henry D. Tazelaar, Yalun Li, Tobias Peikert +7 more